Skip to main content

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Completed · Phase 2 · NCT06602219

Conditions: Plaque Psoriasis

At a glance

Research payments reported, 2025
$1.3M
U.S. investigators named
13
Sites paid
13
Planned or actual enrollment
222

About the trial

Sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Tested
LY4100511 (drug), Placebo (drug)
Dates
Started 2024-10-25; completion 2025-09-04
Results posted
Yes

The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.

From ClinicalTrials.gov, last updated 2026-08-18. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $1.3M in research payments for this study in 2025 (13 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Direct Helpers Medical Center $393,359
  • Driven Research LLC $212,746
  • Cahaba Dermatology and Skin Health Center LLC $160,974
  • Dermatology Trial Associates $151,176
  • 113 Efficient Services $82,689
  • Center for Dermatology Clinical Research Inc $74,418
  • Dermatology Research Associates Inc $53,759
  • Center for Clinical Studies LTD LLP $49,911
  • Lawrence J Green MD LLC $32,488
  • Renstar Inc $27,125
  • Northshore University Healthsystem - Evanston Hospital, IL $25,860
  • Zenith Research Inc $6,375
  • Forward Clinical Trials Inc $2,250

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.